Cytopenias & infections following cilta-cel in heavily pretreated patients with R/R multiple myeloma

28 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this video, Danai Dima, MD, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, presents the findings of a study investigating the incidence and management of cytopenias and infections following treatment with ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Dima notes that cytopenias and infections were common long-term complications of cilta-cel treatment and that a significant proportion of deaths were attributed to non-relapse mortality, particularly infections. This highlights the importance of developing optimized supportive care strategies to manage toxicities and improve patient outcomes. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo